I think the difference makes total sense - at this point in time.
We only make money by taking a clip on Acadia's earnings for Daybue, whereas they make/take the overwhelming majority of the money for a few drugs.
Given 2591 does not make any money yet (and until it does), little credit will be given to the potential, at least not in terms of the SP - as much as that frustrates me. Interested parties and the board will give 2591 credit in terms of valuing the company but that won't be reflected in the SP now.
SeanC is correct in my view - we can catchup and double them at least.
NEU Price at posting:
$13.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)